NASDAQ:KYMR Kymera Therapeutics (KYMR) Stock Price, News & Analysis → The Next Step of Their Control Is Here … (From Weiss Ratings) (Ad) Free KYMR Stock Alerts $33.37 +0.02 (+0.06%) (As of 04:00 PM ET) Add Compare Share Share Today's Range$33.22▼$34.1450-Day Range$33.35▼$43.5752-Week Range$9.60▼$45.31Volume451,996 shsAverage Volume727,638 shsMarket Capitalization$2.04 billionP/E RatioN/ADividend YieldN/APrice Target$41.20 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Kymera Therapeutics alerts: Email Address Kymera Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.54 Rating ScoreUpside/Downside23.5% Upside$41.20 Price TargetShort InterestBearish15.87% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.39Based on 11 Articles This WeekInsider TradingSelling Shares$19.62 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.15) to ($3.44) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.74 out of 5 starsMedical Sector831st out of 908 stocksBiological Products, Except Diagnostic Industry139th out of 147 stocks 3.3 Analyst's Opinion Consensus RatingKymera Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.54, and is based on 7 buy ratings, 6 hold ratings, and no sell ratings.Amount of Analyst CoverageKymera Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 0.0 Short Interest Percentage of Shares Shorted15.87% of the outstanding shares of Kymera Therapeutics have been sold short.Short Interest Ratio / Days to CoverKymera Therapeutics has a short interest ratio ("days to cover") of 14.8, which indicates bearish sentiment.Change versus previous monthShort interest in Kymera Therapeutics has recently increased by 7.06%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldKymera Therapeutics does not currently pay a dividend.Dividend GrowthKymera Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for KYMR. Previous Next 1.9 News and Social Media Coverage News SentimentKymera Therapeutics has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Kymera Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for KYMR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Kymera Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kymera Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $19,624,211.00 in company stock.Percentage Held by Insiders16.67% of the stock of Kymera Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Kymera Therapeutics are expected to decrease in the coming year, from ($3.15) to ($3.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kymera Therapeutics is -13.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kymera Therapeutics is -13.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKymera Therapeutics has a P/B Ratio of 4.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide About Kymera Therapeutics Stock (NASDAQ:KYMR)Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Read More KYMR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KYMR Stock News HeadlinesApril 25, 2024 | globenewswire.comKymera Therapeutics to Report First Quarter 2024 Financial Results on May 2April 24, 2024 | investing.comKymera Therapeutics stock gets Outperform rating on positive outlookApril 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. April 24, 2024 | nasdaq.comCommit To Buy Kymera Therapeutics At $17.50, Earn 9% Annualized Using OptionsApril 23, 2024 | msn.comOppenheimer Initiates Coverage of Kymera Therapeutics (KYMR) with Outperform RecommendationApril 23, 2024 | americanbankingnews.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Consensus Rating of "Moderate Buy" from AnalystsApril 23, 2024 | americanbankingnews.comKymera Therapeutics (NASDAQ:KYMR) Receives New Coverage from Analysts at OppenheimerApril 22, 2024 | benzinga.comKymera Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)April 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. April 16, 2024 | americanbankingnews.comShort Interest in Kymera Therapeutics, Inc. (NASDAQ:KYMR) Increases By 8.8%April 8, 2024 | finanznachrichten.deKymera Therapeutics, Inc.: Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual MeetingApril 8, 2024 | globenewswire.comKymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual MeetingMarch 28, 2024 | investing.comKymera Therapeutics Inc (KYMR)March 20, 2024 | finance.yahoo.comKYMR May 2024 30.000 callMarch 19, 2024 | finance.yahoo.comKYMR Aug 2024 20.000 putMarch 18, 2024 | bizjournals.comBiotech upgrades to new Watertown digs with triple the spaceMarch 8, 2024 | globenewswire.comKymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual MeetingMarch 5, 2024 | finance.yahoo.comInsider Sell: CFO Bruce Jacobs Sells 3,934 Shares of Kymera Therapeutics Inc (KYMR)March 3, 2024 | finance.yahoo.comAnalysts' Revenue Estimates For Kymera Therapeutics, Inc. (NASDAQ:KYMR) Are Surging HigherFebruary 28, 2024 | globenewswire.comKymera Therapeutics to Participate in Upcoming March Investor ConferencesFebruary 27, 2024 | markets.businessinsider.comPiper Sandler Keeps Their Buy Rating on Kymera Therapeutics (KYMR)February 27, 2024 | markets.businessinsider.comPiper Sandler Maintains Overweight Rating for Kymera Therapeutics: Here's What You Need To KnowFebruary 26, 2024 | markets.businessinsider.comMaintaining Hold on Kymera Therapeutics Amidst Promising Pipeline and Industry ChallengesFebruary 24, 2024 | finance.yahoo.comEarnings Update: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported And Analysts Are Trimming Their ForecastsFebruary 24, 2024 | benzinga.comKymera Therapeutics Stock (NASDAQ:KYMR) Dividends: History, Yield and DatesFebruary 23, 2024 | markets.businessinsider.comBreaking Down Kymera Therapeutics: 4 Analysts Share Their ViewsFebruary 23, 2024 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on Kymera Therapeutics (KYMR)See More Headlines Receive KYMR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kymera Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today4/26/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:KYMR CUSIPN/A CIK1815442 Webwww.kymeratx.com Phone857-285-5300FaxN/AEmployees187Year FoundedN/APrice Target and Rating Average Stock Price Target$41.20 High Stock Price Target$56.00 Low Stock Price Target$24.00 Potential Upside/Downside+23.5%Consensus RatingModerate Buy Rating Score (0-4)2.54 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($2.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-146,960,000.00 Net Margins-187.00% Pretax Margin-186.99% Return on Equity-34.83% Return on Assets-25.30% Debt Debt-to-Equity RatioN/A Current Ratio4.73 Quick Ratio4.73 Sales & Book Value Annual Sales$78.59 million Price / Sales25.93 Cash FlowN/A Price / Cash FlowN/A Book Value$7.12 per share Price / Book4.68Miscellaneous Outstanding Shares61,110,000Free Float50,925,000Market Cap$2.04 billion OptionableOptionable Beta2.27 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Bruce L. Booth DPHIL (Age 50)Ph.D., Co-Founder & Chairman Comp: $79.19kDr. Nello Mainolfi M.D. (Age 46)Ph.D., Co-Founder, President, CEO & Director Comp: $975.2kMr. Bruce N. Jacobs CFAChief Financial OfficerDr. Jared A. Gollob M.D. (Age 59)Chief Medical Officer Comp: $637.81kDr. Jeremy G. Chadwick Ph.D. (Age 61)Chief Operating Officer Ms. Ellen V. Chiniara Esq. (Age 65)J.D., Chief Legal Officer & Corporate Secretary Ms. Karen WeisbachHead of People & CultureDr. Juliet Williams B.A Ph.D.Head of ResearchMore ExecutivesKey CompetitorsVericelNASDAQ:VCELDenali TherapeuticsNASDAQ:DNLICG OncologyNASDAQ:CGONBeam TherapeuticsNASDAQ:BEAMGinkgo BioworksNYSE:DNAView All CompetitorsInsiders & InstitutionsCongress Asset Management Co. MABought 533 shares on 4/11/2024Ownership: 0.075%Los Angeles Capital Management LLCSold 3,737 shares on 4/5/2024Ownership: 0.010%Bruce BoothSold 71,764 sharesTotal: $2.90 M ($40.46/share)Venture Fund X L.P. AtlasSold 115,090 sharesTotal: $4.86 M ($42.23/share)Bruce BoothSold 139,255 sharesTotal: $5.88 M ($42.23/share)View All Insider TransactionsView All Institutional Transactions KYMR Stock Analysis - Frequently Asked Questions Should I buy or sell Kymera Therapeutics stock right now? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kymera Therapeutics in the last twelve months. There are currently 6 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" KYMR shares. View KYMR analyst ratings or view top-rated stocks. What is Kymera Therapeutics' stock price target for 2024? 13 Wall Street research analysts have issued twelve-month target prices for Kymera Therapeutics' stock. Their KYMR share price targets range from $24.00 to $56.00. On average, they anticipate the company's share price to reach $41.20 in the next twelve months. This suggests a possible upside of 23.5% from the stock's current price. View analysts price targets for KYMR or view top-rated stocks among Wall Street analysts. How have KYMR shares performed in 2024? Kymera Therapeutics' stock was trading at $25.46 at the start of the year. Since then, KYMR shares have increased by 31.1% and is now trading at $33.37. View the best growth stocks for 2024 here. Are investors shorting Kymera Therapeutics? Kymera Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 9,060,000 shares, an increase of 8.8% from the March 15th total of 8,330,000 shares. Based on an average daily trading volume, of 752,000 shares, the short-interest ratio is presently 12.0 days. View Kymera Therapeutics' Short Interest. When is Kymera Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our KYMR earnings forecast. How can I listen to Kymera Therapeutics' earnings call? Kymera Therapeutics will be holding an earnings conference call on Thursday, May 2nd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link. How were Kymera Therapeutics' earnings last quarter? Kymera Therapeutics, Inc. (NASDAQ:KYMR) issued its quarterly earnings results on Thursday, February, 22nd. The company reported ($0.25) earnings per share for the quarter, beating analysts' consensus estimates of ($0.44) by $0.19. The firm earned $47.90 million during the quarter, compared to analysts' expectations of $41.94 million. Kymera Therapeutics had a negative trailing twelve-month return on equity of 34.83% and a negative net margin of 187.00%. The firm's revenue was up 197.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.60) earnings per share. What ETFs hold Kymera Therapeutics' stock? ETFs with the largest weight of Kymera Therapeutics (NASDAQ:KYMR) stock in their portfolio include Simplify Propel Opportunities ETF (SURI), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Harbor Disruptive Innovation ETF (INNO) and First Trust Small Cap Growth AlphaDEX Fund (FYC).First Trust Nasdaq Pharmaceuticals ETF (FTXH). What other stocks do shareholders of Kymera Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kymera Therapeutics investors own include Harbor Custom Development (HCDI), Gores Holdings V (GRSVU), FS Development (FSDC), Freeline Therapeutics (FRLN), Duck Creek Technologies (DCT), CureVac (CVAC), Checkmate Pharmaceuticals (CMPI), Burlington Stores (BURL), BigCommerce (BIGC) and KE (BEKE). When did Kymera Therapeutics IPO? Kymera Therapeutics (KYMR) raised $126 million in an initial public offering on Friday, August 21st 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Securities, Cowen and Guggenheim Securities served as the underwriters for the IPO. Who are Kymera Therapeutics' major shareholders? Kymera Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Congress Asset Management Co. MA (0.08%) and Los Angeles Capital Management LLC (0.01%). Insiders that own company stock include Bruce Booth, Bruce N Jacobs, Bruce N Jacobs, Bvf Partners L P/Il, Ellen Chiniara, Jared Gollob, Jeffrey W Albers, Nello Mainolfi, Richard Chesworth and Venture Fund X LP Atlas. View institutional ownership trends. How do I buy shares of Kymera Therapeutics? Shares of KYMR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:KYMR) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kymera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
